Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
1 minute read

Anemia Advantage For GSK’s Blood Cancer Therapy Could Influence Market Share Despite Incyte’s Jakafi Comparison

By Vandana Singh
September 18, 1:59 PM
Friday, the FDA approved GSK plc's (NYSE: GSK) Ojjaara (momelotinib) for intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and post-essential thrombocythaemia), in 

BMY

Read More
2 minute read

Bristol Myers Squibb’s Opdivo Plus Yervoy Combo Shows Durable, Long-Term Survival In Lung Cancer Patients

By Vandana Singh
September 11, 2:10 PM
Bristol Myers Squibb & Co (NYSE: BMY) announced six-year results from Part 1 of the Phase 3 CheckMate -227 trial, which continues to demonstrate long-term, durable survival benefits of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to chemotherapy in the first-line treatment of patients with met

BMY

Read More
1 minute read

Bristol Myers Squibb’s Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer

By Benzinga Newsdesk
September 11, 7:00 AM
Bristol Myers Squibb (NYSE:BMY) today announced six-year results from Part 1 of the Phase 3 CheckMate -227 trial, which continues to demonstrate long-term, durable survival benefits

BMY